Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026

PSNL vs IMDX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

PSNL Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 5–3 Matrix Metrics)

PSNL Overall Winner 6-Pillar Tally: PSNL 3 – 2 IMDX (1 Tie) Matrix Metrics: PSNL 5 – 3 IMDX

As of Nov 19, 2026, Personalis, Inc. (PSNL) is the stronger overall head-to-head candidate over Insight Molecular Diagnostics Inc. (IMDX) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). PSNL carries a Unified Composite Score of 43.3/100 (HOLD) at $14.72 (N/M Forward P/E, -156.7% operating margin), whereas IMDX carries 45.5/100 (HOLD) at $1.66 (N/M Forward P/E, -1883.2% operating margin).

  • Composite vs. Pillar Nuance: While IMDX currently prints a higher short-term Unified Composite Score (45.5/100 HOLD vs. PSNL 43.3/100 HOLD), PSNL captures the overall institutional head-to-head verdict (5–3 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (-156.7% vs. -1883.2% operating margin) and revenue trajectory (+76.6% vs. +115.0% YoY).
  • Technical & Structure Timing Caution: PSNL is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 30.2); meanwhile IMDX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 21.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About PSNL vs IMDX
PSNL NASDAQ Head-to-Head Winner
Personalis, Inc. Common Stock
Services-Medical Laboratories
$14.72
-1.74% 1D
Market Cap $1.6B
TTM Revenue $81M
Forward P/E N/M
Beta / 30D Vol 1.69β · 23% Vol
Unified Composite Score
43.3 / 100 HOLD
Tech 22.0 Fund 58.0 Flow 58.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -1.7%), weak momentum, RSI 30
RSI-14: 30.2 · SMA20: $15.64 · SMA50: $15.93
IMDX NASDAQ
Insight Molecular Diagnostics Inc. Common Stock
In Vitro & In Vivo Diagnostic Substances
$1.66
+4.4% 1D
Market Cap $52.1M
TTM Revenue $2.0M
Forward P/E N/M
Beta / 30D Vol 2.91β · 76% Vol
Unified Composite Score
45.5 / 100 HOLD
Tech 50.0 Fund 40.0 Flow 58.0 Mom 40.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -17.7%), weak momentum, RSI 22
RSI-14: 21.9 · SMA20: $2.51 · SMA50: $3.10

6-Pillar Scorecard Institutional Category Breakdown (PSNL 3 – 2 IMDX)

Columns: Metric · PSNL · IMDX
1. Valuation Multiples IMDX
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 19.3x 18.8x
2. Growth & Scale PSNL
Revenue Growth (YoY) +76.6% +115.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $81M $2.0M
Market Cap $1.6B $52.1M
3. Profitability & Quality PSNL
Gross Margin 16.7% 55.6%
Operating Margin -156.7% -1883.2%
Net Profit Margin -147.7% 0.0%
Return on Equity (ROE) -62.1% -23603.1%
4. Balance Sheet & Cash Flow IMDX
Cash Generation (TTM) -$108M -$31M
Cash Flow Margin N/A N/A
Net Cash / Leverage $61M Net Cash $15M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning PSNL
Options Structure Phase CONSOLIDATION BREAKDOWN
Current IV / %ile 32.9% (2nd %ile) 99.4% (12th %ile)
Put/Call OI Skew N/A 0.08x (Call-Skewed)
OBV Trend / Tech Phase DISTRIBUTION · Markdown DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Diagnostics & Research Operator Diagnostics & Research Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: PSNL (5) vs IMDX (3)
Institutional Metric PSNL IMDX Criterion Row Edge
Market Capitalization
Scale
$1.6B $52.1M Larger Scale PSNL
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+76.6% +115.0% Higher Growth IMDX
Operating Margin (TTM)
Profitability
-156.7% -1883.2% Higher Margin PSNL
Net Profit Margin
Profitability
-147.7% 0.0% Higher Margin IMDX
Return on Equity (ROE)
Capital Efficiency
-62.1% -23603.1% Higher ROE PSNL
52-Week Range Position
Momentum
70% ($5–$19) 3% ($2–$8) Stronger Trend PSNL
Beta / 30D Volatility
Risk Regime
1.69β · 23% Vol 2.91β · 76% Vol Lower Realized Risk PSNL
Unified Institutional Score
Composite Signal
43.3 / 100 (HOLD) 45.5 / 100 (HOLD) Higher Composite IMDX
Trailing 12M Revenue (USD)
Operating Scale
$81M $2.0M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
16.7% 55.6% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 19.3x EV/Rev N/M PEG · 18.8x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$108M ($61M Net Cash) -$31M ($15M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon PSNL +37.61 pp
PSNL: -7.42% · IMDX: -45.03%
3M Horizon PSNL +41.84 pp
PSNL: -19.91% · IMDX: -61.75%
6M Horizon PSNL +150.19 pp
PSNL: +78.42% · IMDX: -71.77%
1Y Horizon PSNL +166.96 pp
PSNL: +93.18% · IMDX: -73.78%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period PSNL Revenue IMDX Revenue PSNL Op. Margin IMDX Op. Margin Margin Leader
FY2018 $40M N/A -36.5% N/A PSNL
FY2019 $70M N/A -34.4% N/A PSNL
FY2020 $80M $0M -53.6% -2443.3% PSNL
FY2021 $90M $0M -76.4% -2444.3% PSNL
FY2022 $70M $0M -177.6% -1878.6% PSNL
FY2023 $70M $0M -149.6% -1672.4% PSNL
FY2024 $80M $0M -80.7% -3245.1% PSNL
FY2025 $70M $0M -126.4% -1260.8% PSNL

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
PSNL CONSOLIDATION
90d in phase · OBV DISTRIBUTION
Current IV 32.9%
IV Percentile 2nd %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact PSNL Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
IMDX BREAKDOWN
117d in phase · OBV DISTRIBUTION
Current IV 99.4%
IV Percentile 12th %ile
Put/Call OI Skew 0.08x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact IMDX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
PSNL Moat Profile Cyclical / Execution-Driven Positioning
Diagnostics & Research Operator
Competes within the Diagnostics & Research value chain with $1.6B market capitalization and -156.7% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
IMDX Moat Profile Cyclical / Execution-Driven Positioning
Diagnostics & Research Operator
Competes within the Diagnostics & Research value chain with $52.1M market capitalization and -1883.2% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ PSNL vs IMDX Key Questions & Quantitative Answers

As of Nov 19, 2026, Personalis, Inc. (PSNL) is the stronger overall head-to-head candidate over Insight Molecular Diagnostics Inc. (IMDX) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). PSNL carries a Unified Composite Score of 43.3/100 (HOLD) at $14.72 (N/M Forward P/E, -156.7% operating margin), whereas IMDX carries 45.5/100 (HOLD) at $1.66 (N/M Forward P/E, -1883.2% operating margin). Composite vs. Pillar Nuance: While IMDX currently prints a higher short-term Unified Composite Score (45.5/100 HOLD vs. PSNL 43.3/100 HOLD), PSNL captures the overall institutional head-to-head verdict (5–3 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (-156.7% vs. -1883.2% operating margin) and revenue trajectory (+76.6% vs. +115.0% YoY). Technical & Structure Timing Caution: PSNL is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 30.2); meanwhile IMDX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 21.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

PSNL leads the Growth & Scale pillar: PSNL posts +76.6% YoY revenue growth and +0.0% YoY earnings growth on $81M TTM revenue (16.7% gross margin, -156.7% operating margin), compared with IMDX at +115.0% YoY revenue growth and +0.0% YoY earnings growth on $2.0M TTM revenue (55.6% gross margin, -1883.2% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), PSNL cumulative revenue shifted +75.0% while IMDX shifted N/A. In operating R&D and SG&A reinvestment, PSNL deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for IMDX.

IMDX screens cheaper on headline valuation multiples. PSNL trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 19.3x EV/Revenue (unreported FCF margin), whereas IMDX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 18.8x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against PSNL (-62.1% ROE) versus IMDX (-23603.1% ROE) capital efficiency.

In options market volatility and institutional positioning, PSNL carries 32.9% implied volatility (2nd %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.69β · 23% Vol realized risk). By comparison, IMDX carries 99.4% implied volatility (12th %ile, Compressed (<25th %ile)), a 0.08x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (2.91β · 76% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.